Trump’s Teva and Astellas “most-favored-nation” deals shift drug-price risk toward manufacturers—and toward PBMs’ net-price math

On Aug. 31, 2026, the administration disclosed a new round of voluntary bilateral drug-pricing agreements (framed as “most-favored nation” access for participating state Medicaid programs) that explicitly include Teva and Astellas Pharma. The disclosure also ties participation to practical commitments that go beyond simple talk—most notably, the administration says the companies will contribute active pharmaceutical ingredients (APIs) to U.S. strategic reserves.

This is analytically different from the IRA library-and-bid process. Under the new bilateral structure as described by the administration, the political lever is price comparability (and related operational commitments) negotiated directly with manufacturers, then made available to state Medicaid programs. That changes who carries the immediate execution risk: manufacturers must align pricing behavior to the MFN-style standard, while payers (including PBMs operating behind employer and plan contracts) must re-model the list-price-to-net-price channel.

A key load-bearing element in the administration’s broader disclosure of these bilateral agreements is the operational commitment: participating companies would contribute APIs to the country’s strategic reserves. In the Aug. 31, 2026 coverage summarizing the new round, UCB , Sun Pharmaceutical , Teva and Astellas Pharma are cited together for a combined contribution of 290 metric tons of APIs.

While the headlines focus on price cuts, the API commitment is a second-order but investor-relevant contract feature. It effectively increases the “cost of delay” for non-compliance: manufacturers are not only adjusting pricing for U.S. channels; they are also funding/producing capacity that supports domestic resilience. That makes voluntary MFN participation stickier than a purely paper commitment.

To see why the transmission channel matters, look at the companies’ recent financial shape. For example, Teva reported FY2024 revenue of $16.54B and FY2024 net income of -$1.64B (with FY2024 net cash from operating activities of $1.25B and free cash flow of $0.75B). Those fundamentals imply that a sustained net-realization squeeze (even without collapsing volume) can matter disproportionately for investor confidence around future profitability.

For Astellas Pharma, the company’s latest available annual income statement data in this build shows FY2025 revenue of ¥1.91T and net income of ¥50.7B. A voluntary MFN approach can pressure net realization on eligible products even if overall demand remains intact—because discounts and rebates are exactly the levers that tend to adjust first when a pricing ceiling is imposed.

The administration’s naming of both a major generic/specialty supplier like Teva and a Japanese branded pharmaceutical company like Astellas Pharma suggests this voluntary-deal playbook is designed to be portfolio-agnostic. The market implication: if MFN constraints bite both on generics and brands, then investors should treat the policy risk as sector-wide rather than a “branded-only” or “IRA-only” narrative.

In the IRA framework, negotiation coverage is defined by a selected-drug list, creating a narrower “first-order” set of affected SKUs. A bilateral voluntary playbook—if it scales—can expand the set of price-constrained products through incremental signings and state program adoption, potentially altering net-price expectations faster than the IRA selection cadence.

That makes the signatory roster—and the inclusion of both Teva and Astellas Pharma—more than political theater. It is a signal about how quickly the industry could be forced to price to an MFN-style reference point across more payers and channels.